Harel Insurance Investments & Financial Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-54,425
| Closed | -$7.43M | – | 530 |
|
|
2024
Q4 | $7.43M | Buy |
54,425
+18,797
| +53% | +$2.57M | 0.12% | 69 |
|
|
2024
Q3 | $4.11M | Buy |
35,628
+13,936
| +64% | +$1.61M | 0.07% | 86 |
|
|
2024
Q2 | $2.91M | Buy |
+21,692
| New | +$2.91M | 0.05% | 105 |
|
|
2019
Q2 | – | Sell |
-146
| Closed | -$13K | – | 513 |
|
|
2019
Q1 | $13K | Sell |
146
-135
| -48% | -$12K | ﹤0.01% | 389 |
|
|
2018
Q4 | $20K | Sell |
281
-5
| -2% | -$356 | ﹤0.01% | 384 |
|
|
2018
Q3 | $35K | Buy |
286
+65
| +29% | +$7.96K | ﹤0.01% | 381 |
|
|
2018
Q2 | $22K | Buy |
+221
| New | +$22K | ﹤0.01% | 386 |
|